Societal cost-effectiveness analysis of the 21-gene assay in early-stage breast cancer in Japan

"The 21-gene assay for women with estrogen-receptor–positive, lymph-node–negative, early-stage breast cancer is projected to be cost-effective in Japan."

Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor–positive, lymph-node–negative early-stage breast cancer in Japan
H Yamauchi et al.
BMC Health Services Research 2014, 14:372

Read more here.